Summary
ZIOPHARM is seeking to in-license clinical stage drugs for cancer treatment.Organization name
ZIOPHARM Oncology, IncProfile
ZIOPHARM Oncology is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. ZIOPHARM currently has three compounds in phase I/II trials, and expects multiple data points in all programs over the next 12 months. In addition, following discussions with appropriate health authorities, the Company expects the commencement of a registration study to begin in 2H08.
We are looking throughout the world, and we actively encourage partnering or business development managers to contact us with in-licensing proposals. You will find ZIOPHARM to be extremely responsive to your inquiries.
Our business model is based on developing licensed drugs. ZIOPHARM's value is based on the clinical quality of the drugs we develop, and the timelines to FDA submission and licensure. We are professionally, ethically and financially motivated to move drugs through clinical trial phases as efficiently as possible.We are closely aligned with the clinical and drug development strategies embodied in the early drafts of the FDA's Critical Path Initiative, designed to streamline drug development. It sets forth a clear willingness and openness to considering new ways of approaching trial design and endpoint selection, including the use of biomarkers as surrogate endpoints and computer modeling and simulation to streamline the clinical trial process.Each product entering the ZIOPHARM pipeline will be evaluated carefully to determine the best enrichment strategy for speed-to-market and the best return on investment. We will analyze clinical trial results using the extremely vigorous standards of current clinical trial practice.
Business development contacts are provided online.
Description File
051908_CorporateProfile.pdf
print this page
